Discounted Cash Flow
Adaptive Biotechnologies Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $38.4m | $-42.8m | $-37.3m | -111.4% | — |
| 2018 | $55.7m (44.8%) | $-46.4m (-8.4%) | $-38.6m (-3.5%) | -83.4% (25.1%) | — |
| 2019 | $85.1m (52.8%) | $-68.6m (-47.7%) | $194.2m (603.4%) | -80.6% (3.4%) | $1.00 |
| 2020 | $98.4m (15.6%) | $-146.2m (-113.1%) | $-168.5m (-186.8%) | -148.6% (-84.3%) | $-1.11 (-211.0%) |
| 2021 | $154.3m (56.9%) | $-207.3m (-41.8%) | $-254.5m (-51.0%) | -134.3% (9.6%) | $-1.48 (-33.3%) |
| 2022 | $185.3m (20.1%) | $-200.2m (3.4%) | $-200.3m (21.3%) | -108.0% (19.6%) | $-1.40 (5.4%) |
| 2023 | $170.3m (-8.1%) | $-225.2m (-12.5%) | $-167.0m (16.6%) | -132.3% (-22.5%) | $-1.56 (-11.4%) |
| 2024 | $179.0m (5.1%) | $-159.5m (29.2%) | $-98.9m (40.8%) | -89.1% (32.6%) | $-1.08 (30.8%) |
| 2025 | $277.0m (54.8%) | $-59.5m (62.7%) | $-48.9m (50.5%) | -21.5% (75.9%) | $-0.39 (63.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.